TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03299218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SNF (Wawamum)
Description: A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SNF (Wawamum)
Description: A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social and behaviour change communication (SBCC)
Description: SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social and behaviour change communication (SBCC)
Description: SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash
Description: Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash
Description: Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash
Description: Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash
Description: Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
Study: NCT02525146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention
Study: NCT00263393

Intervention type: DRUG
Group type: OTHER
Intervention: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin
Description: The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Promotion
Description: The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
Study: NCT02507271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Fitness Program
Description: This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Weekly Telephone Contact
Description: This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
Study: NCT02015286

Intervention type: DEVICE
Intervention: easypod™
Description: Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
Study: NCT01861600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S-26 Gold
Description: (13.4 g/L protein) with 100% Fat Blend A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-26 Gold EF1
Description: (13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-26 Gold EF2
Description: (13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-26 Gold EF3
Description: (13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose

Intervention type: OTHER
Group type: OTHER
Intervention: Human Milk
Description: Human Milk
Study: NCT02145000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine (BRV-PV)
Description: Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05395702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Gamma
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study: NCT02099331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Melatonin)
Description: Sugar pill manufactured to mimic Melatonin 20 mg
Study: NCT02545712

Intervention type: OTHER
Intervention: Exposure to benzyl alcohol
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to benzyl alcohol
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to acesulfam potassium
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to acesulfam potassium
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to aspartame
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to aspartame
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to glycerol
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to glycerol
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to sorbitol
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to sorbitol
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to methyl-p-hydroxybenzoate
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to methyl-p-hydroxybenzoate
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to propanyl-p-hydroxybenzoate
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to propanyl-p-hydroxybenzoate
Description: The drug source(s) and amount administered daily are noted.

Intervention type: OTHER
Intervention: Exposure to polysorbate-80
Description: The drug source(s) and amount administered daily are noted.
Study: NCT04335994

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In-laboratory polysomnography
Description: Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Sleep Apnea Test
Description: Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
Study: NCT02545712

Intervention type: OTHER
Intervention: Exposure to polysorbate-80
Description: The drug source(s) and amount administered daily are noted.
Study: NCT02065128

Intervention type: OTHER
Intervention: Capsaicin cough challenge test
Description: The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
Study: NCT00045396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study: NCT02487979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glembatumumab Vedotin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02710630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate tablet E1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate tablet D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate tablet C1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate tablet B1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate tablet A1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate capsule
Study: NCT03681301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality simulator
Description: Additional self-directed learning and practice using virtual reality simulator
Study: NCT02409485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Skill-Training (CST)
Description: Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
Study: NCT03934229

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily intake of study product
Description: Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Daily intake of study product
Description: Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
Study: NCT00995449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB003
Description: KB003 IV x5 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB003
Description: KB003 IV x5 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB003
Description: KB003 IV x5 doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo IV x5 doses
Study: NCT00047463

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure (CPAP)
Description: a mask treatment for sleep apnea

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-CPAP
Description: Placebo-CPAP
Study: NCT02421991

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Delivered Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Delivered Intervention
Study: NCT04233814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Description: LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Description: LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Description: LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Description: LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Description: LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Description: LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Description: LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Description: LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
Study: NCT04067141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A
Description: Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A
Description: Contact Lens
Study: NCT01259986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Laser treatment of using 635 nm laser with a dose of 3.0 J/cm\^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
Study: NCT00393445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 control
Description: intravenous infusion of GLP-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 and Exendin(9-39) 300
Description: intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline control
Description: intravenous infusion of saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 and Exendin(9-39) 600
Description: intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 and Exendin(9-39) 900
Description: intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 and Exendin(9-39) 1200
Description: intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
Study: NCT00058305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04321460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LRG-002
Description: Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing placebo
Study: NCT01368458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversion to Antipsychotic Monotherapy
Description: Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
Study: NCT00642304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
Description: Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
Study: NCT03617809

Intervention type: PROCEDURE
Intervention: Preoperative warming
Description: The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
Study: NCT01709227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output \>1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis
Description: Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
Study: NCT04695691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera Laser System
Description: Subjects will receive laser treatments
Study: NCT06270121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living-lab digital intervention group
Description: Older adults will receive individualized daily health feedback via the mobile applications, which will be shared with caregivers. They will also receive support for health emergency by the platform sending automatic emergency push alarm to community and family caregivers.
Study: NCT04589559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback Training
Description: First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
Study: NCT03217136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: Ceftolozane 20 mg/kg (maximum 1 g) and tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants ≤ 28 days old, start with a loading dose of 15 mg/kg; then if ≤ 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if \> 2 kg are dosed 10 mg/kg every 8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Metronidazole
Description: Placebo for metronidazole administered IV every 8 hours for between 5 to 14 days.
Study: NCT02487979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02618252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zonare
Description: Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veinviewer
Description: Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
Study: NCT02703779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
Study: NCT01183793

Intervention type: RADIATION
Group type: OTHER
Intervention: Barium follow-through and MR-enterography
Description: Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test

Intervention type: RADIATION
Group type: OTHER
Intervention: Barium follow-through and MR-enterography
Description: Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
Study: NCT02418260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bridge Plate osteosynthesis
Description: Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Locked intramedullary nail osteosynthesis
Description: Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and plate osteosynthesis
Description: Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
Study: NCT02703779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.